Author:
Xue Xuemin,Guo Lei,Guo Changyuan,Xu Liwei,Li Lin,Yang Lin,Wang Xin,Rao Wei,Yuan Pei,Mu Jiali,Li Jiangtao,Wang Bingning,Zhou Quan,Xue Weicheng,Ma Fei,Yang Wenjing,Ying Jianming
Funder
the National Anti-Tumor Drug Surveillance System of National Cancer Center
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. Cancer J Clin. 2016;66(2):115–32.
3. Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.Version 4.2022; 2022.
5. WHO Classification of Tumours Editorial Board. Breast tumours. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th ed.; vol.2) https://publications.iarc.fr/581; 2019.